Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
Abivax (Euronext: ABVX, Nasdaq: ABVX), a clinical-stage biotechnology company, has been selected to join the CAC Mid 60 and SBF 120 indices following Euronext Paris's annual review. The inclusion will become effective on September 19, 2025, after market close.
The company, which focuses on developing therapeutics for chronic inflammatory diseases, expects this inclusion to enhance its visibility and broaden its investor base, particularly among institutional investors and index-linked funds. CEO Marc de Garidel highlighted this achievement as a validation of the company's strategic vision and execution capabilities.
Abivax (Euronext: ABVX, Nasdaq: ABVX), una società biotecnologica in fase clinica, è stata selezionata per entrare negli indici CAC Mid 60 e SBF 120 in seguito alla revisione annuale di Euronext Paris. L’inclusione avrà effetto dopo la chiusura del mercato il 19 settembre 2025.
L’azienda, che si occupa di sviluppare terapie per malattie infiammatorie croniche, si aspetta che questa inclusione aumenti la sua visibilità e amplii la base di investitori, in particolare tra investitori istituzionali e fondi indicizzati. Il CEO Marc de Garidel ha evidenziato questo traguardo come una convalida della visione strategica e delle capacità di esecuzione dell’azienda.
Abivax (Euronext: ABVX, Nasdaq: ABVX), una empresa biotecnológica en fase clínica, ha sido seleccionada para incorporarse a los índices CAC Mid 60 y SBF 120 tras la revisión anual de Euronext Paris. La inclusión entrará en vigor después del cierre del mercado el 19 de septiembre de 2025.
La empresa, que se centra en desarrollar terapias para enfermedades inflamatorias crónicas, espera que esta inclusión aumente su visibilidad y amplíe su base de inversores, especialmente entre inversores institucionales y fondos vinculados a índices. El CEO Marc de Garidel destacó este logro como una validación de la visión estratégica y de la capacidad de ejecución de la compañía.
Abivax (Euronext: ABVX, Nasdaq: ABVX), 임상단계 생명공학 회사가 파리 증권거래소의 연례 검토에 따라 CAC Mid 60 및 SBF 120 지수에 편입되도록 선정되었습니다. 편입은 2025년 9월 19일 장 마감 후 발효됩니다.
만성 염증성 질환에 대한 치료제를 개발하는 이 회사는 이번 편입으로 가시성이 높아지고 기관 투자자 및 인덱스 연계 펀드들 사이에서 투자자 기반이 확대될 것으로 기대합니다. Marc de Garidel CEO는 이 성과를 회사의 전략적 비전과 실행 역량의 검증으로 강조했습니다.
Abivax (Euronext: ABVX, Nasdaq: ABVX), une société biotechnologique en phase clinique, a été sélectionnée pour rejoindre les indices CAC Mid 60 et SBF 120 après l’examen annuel d’Euronext Paris. L’inclusion entrera en vigueur après la clôture du marché le 19 septembre 2025.
L’entreprise, qui se concentre sur le développement de thérapies pour les maladies inflammatoires chroniques, s’attend à ce que cette inclusion renforce sa visibilité et élargisse sa base d’investisseurs, en particulier parmi les investisseurs institutionnels et les fonds liés aux indices. Le PDG Marc de Garidel a qualifié cette réalisation de validation de la vision stratégique et des capacités d’exécution de l’entreprise.
Abivax (Euronext: ABVX, Nasdaq: ABVX), ein biotechnologisches Unternehmen im klinischen Stadium, wurde ausgewählt, um den Indizes CAC Mid 60 und SBF 120 beizutreten, nach der jährlichen Überprüfung von Euronext Paris. Die Aufnahme wird nach Handelsschluss am 19. September 2025 wirksam.
Das Unternehmen, das Therapien für chronisch entzündliche Erkrankungen entwickelt, erwartet, dass diese Aufnahme seine Sichtbarkeit erhöht und seine Investorenbasis erweitert, insbesondere unter institutionellen Investoren und indexgebundene Fonds. CEO Marc de Garidel bezeichnete diese Errungenschaft als Validierung der strategischen Vision und der Umsetzungskompetenz des Unternehmens.
Abivax (Euronext: ABVX, Nasdaq: ABVX)، شركة تكنولوجيا حيوية في مرحلة klinية، قد اختيرت للانضمام إلى مؤشرات CAC Mid 60 و SBF 120 عقب المراجعة السنوية من Euronext Paris. ستكون الإضافة سارية المفعول بعد إغلاق السوق في 19 سبتمبر 2025.
تتطلع الشركة، التي تركز على تطوير علاجات للأمراض الالتهابية المزمنة، إلى أن تعزز هذه الإضافة من وضوحها وتوسع قاعدة المستثمرين لديها، خاصة بين المستثمرين المؤسسيين وصناديق المؤشرات المرتبطة بالمؤشرات. وأشار الرئيس التنفيذي مارك دي غاريدل إلى أن هذا الإنجاز يمثل اعتماداً على الرؤية الإستراتيجية للشركة وقدرات تنفيذها.
Abivax (Euronext: ABVX, Nasdaq: ABVX)，一家处于临床阶段的生物技术公司，在Euronext Paris年度评审后被选入 CAC Mid 60 与 SBF 120 指数。此次并入将于市场收盘后于2025年9月19日生效。
该公司专注于开发慢性炎症性疾病的治疗药物，预计此次并入将提升其知名度并扩大投资者基础，特别是在机构投资者和指数型基金之间。CEO Marc de Garidel 将此成就视为对公司战略愿景与执行能力的验证。
- Inclusion in prestigious CAC Mid 60 and SBF 120 indices
- Expected increase in visibility to institutional investors
- Potential broader investor base through index-linked funds
- None.
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
PARIS, France, September 12, 2025, 5:45 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today that following the annual review of the Euronext Paris indices on September 11, 2025, the Scientific Council of the Indices has decided to admit Abivax to the CAC Mid 60 and SBF 120 indices.
This decision will take effect on Friday, September 19, 2025, after market close.
The CAC Mid 60 and SBF 120 are key indices on the Euronext Paris exchange, representing mid-sized listed companies and a broader selection of 120 major securities, respectively. Inclusion in these indices enhances Abivax’s visibility and is expected to broaden the Company’s investor base by making its shares more accessible to institutional investors and index-linked funds.
"We are honored to be added to the Euronext CAC Mid 60 and SBF 120 indices," said Marc de Garidel, Chief Executive Officer of Abivax. "This recognition is a powerful testament to the financial markets' continued confidence in our strategic visions and our ability to execute them. This milestone also further validates our commitment to advancing innovative therapies for patients with chronic inflammatory diseases while driving long-term value for our shareholders."
*****
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com. Follow us on LinkedIn and on X, formerly Twitter, @ABIVAX.
Contacts:
Abivax Investor Relations
Patrick Malloy
patrick.malloy@abivax.com
+1 847 987 4878
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company’s business and financial objectives. Words such as “design,” “expect,” “forward,” “future,” “potential,” “plan,” “project,” “will” and variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements concerning or implying the therapeutic potential of Abivax's drug candidates, the potential benefits of Abivax being admitted to the CAC Mid 60 and SBF 120 indices, and other statements that are not historical fact. Although Abivax’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its universal registration document (Document d’Enregistrement Universel) and in its Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 24, 2025 under the caption “Risk Factors.” These risks, contingencies and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates. and the availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development including further assessment by the Company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.
FAQ
When will Abivax (ABVX) join the CAC Mid 60 and SBF 120 indices?
What are the benefits for Abivax of joining the CAC Mid 60 and SBF 120 indices?
What is Abivax's (ABVX) main business focus?
Who is the CEO of Abivax (ABVX)?
